Nicolas Benziane-Ouaritini
Nicolas Benziane-Ouaritini is an expert in Radiotherapy at Institut Bergonié (France). Nicolas Benziane-Ouaritini has authored 26 publications, the most recent in 2024. SLR score: 70 (community average: 125). How the SLR is computed.
LeadR Profile
Radiotherapy
Subspecialties: Oncology - Urology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2020 - 2024
Number : 26
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Hypofractionated Postprostatectomy Radiotherapy-Less is Really More? PMID 39115817 — radiotherapy, neoplasms | JAMA Oncol | 2024 | 0 |
| Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol. PMID 38755095 — radiotherapy, clinical protocols, disease-free survival, pharmaceutical preparations, androgens, neoplasms, prostate, urologic neoplasms, prostatic neoplasms, therapeutics | Eur Urol Oncol | 2024 | 2 |
| Local Treatment (Primary Tumor and Metastases) in Metastatic Prostate Cancer. PMID 39462742 — urology, neoplasms, prostate, neoplasm metastasis, prostatic neoplasms, therapeutics | Eur Urol Focus | 2024 | 1 |
| Heart is a heavy burden: cardiac toxicity in radiation oncology. PMID 39495349 — radiotherapy, radiation oncology, heart, neoplasms, cardiotoxicity, palliative care | Support Care Cancer | 2024 | 1 |
| Stereotactic body radiation therapy for primary renal cell carcinoma: A review on behalf of the CC-AFU. PMID 38823486 — radiotherapy, cells, neoplasms, carcinoma, renal cell, aged, kidney neoplasms, therapeutics | Fr J Urol | 2024 | 2 |
LeadR Networks
Main global connection map